Technical Analysis for AUP - Aurinia Pharmaceuticals Inc.

Grade Last Price % Change Price Change
F 16.03 -1.48% -0.240
AUP closed down 1.48 percent on Friday, April 9, 2021, on 47 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat
Historical AUP trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -1.48%
Down 3 Days in a Row Weakness 0.19%
Narrow Range Bar Range Contraction -0.80%
NR7 Range Contraction -0.80%
NR7-2 Range Contraction -0.80%
20 DMA Resistance Bearish -1.78%
Narrow Range Bar Range Contraction -1.78%
NR7 Range Contraction -1.78%
NR7-2 Range Contraction -1.78%
20 DMA Resistance Bearish -2.79%
Older End-of-Day Signals for AUP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2% 2 days ago
10 DMA Support 2 days ago
Fell Below Previous Day's Low 2 days ago
Down 1% 2 days ago
Fell Below 10 DMA 2 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aurinia Pharmaceuticals Inc. Description

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Pharma Pharmaceutical Chemical Clinic Drug Disease RTT Therapy Pharmaceuticals Diseases Clinical Trial Biopharmaceutical Stage Biopharmaceutical Peptides Psoriasis Autoimmune Diseases Targeted Therapy Immunosuppressants Lupus

Is AUP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 26.23
52 Week Low 15.18
Average Volume 149,460
200-Day Moving Average 18.868
50-Day Moving Average 18.065
20-Day Moving Average 16.409
10-Day Moving Average 16.073
Average True Range 0.637
ADX 23.43
+DI 16.140
-DI 24.064
Chandelier Exit (Long, 3 ATRs ) 16.138
Chandelier Exit (Short, 3 ATRs ) 17.092
Upper Bollinger Band 17.642
Lower Bollinger Band 15.176
Percent B (%b) 0.35
BandWidth 15.032
MACD Line -0.470
MACD Signal Line -0.568
MACD Histogram 0.0984
Fundamentals Value
Market Cap 2.02 Billion
Num Shares 126 Million
EPS -0.70
Price-to-Earnings (P/E) Ratio -23.00
Price-to-Sales 13913.01
Price-to-Book 4.64
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.630
Resistance 3 (R3) 16.660 16.490 16.530
Resistance 2 (R2) 16.490 16.337 16.475 16.497
Resistance 1 (R1) 16.260 16.243 16.175 16.230 16.463
Pivot Point 16.090 16.090 16.048 16.075 16.090
Support 1 (S1) 15.860 15.937 15.775 15.830 15.597
Support 2 (S2) 15.690 15.843 15.675 15.563
Support 3 (S3) 15.460 15.690 15.530
Support 4 (S4) 15.430